New insider activity at Evolent Health ( (EVH) ) has taken place on March 6, 2025.
Director Brendan B Springstubb has made a significant investment in Evolent Health by purchasing 5,000 shares of the company’s stock. This transaction is valued at $43,750, indicating a strong vote of confidence in the company’s future prospects.
Recent Updates on EVH stock
In the last 24 hours, Evolent Health has experienced significant developments affecting its stock price targets. Citizens JMP raised Evolent’s price target due to management’s efforts to stabilize the business amidst elevated oncology costs, which impacted Q4 revenue and EBITDA. Despite challenges in 2024, the firm expects more predictable profit generation moving forward. Conversely, Piper Sandler lowered its price target, citing Q4 results at the low end of guidance but appreciating the 2025 outlook, which is adjusted for the acceleration in oncology cost trends. Evolent’s recent earnings call revealed strong revenue growth and strategic contract renewals, although challenges persist with oncology expenses and Medicaid headwinds. The company is focusing on efficiency improvements and contract renegotiations to enhance EBITDA, with a cautious outlook for 2025. Evolent’s strategic initiatives, including new partnerships and investments in automation, aim to bolster its market position and financial performance.
More about Evolent Health
YTD Price Performance: -25.59%
Average Trading Volume: 2,435,032
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $996.9M
Questions or Comments about the article? Write to editor@tipranks.com